Like the great fortunes, the valuation of the most capitalized companies on the market is closely linked to that of the United States, with 15 out of 17 among the most listed companies, with those in the technology sector practically dominating this list. Europe, to a lesser extent, can also boast of having some of them, the pharmaceutical industry being at the forefront.
You have to go up to 18th place to find the first most capitalized European company, as is the case Nordisk. The Danish company is valued at $513.37 billion, thanks in part to the drug Ozempic, which has propelled the company beyond even LVMH. The gala ranks second among major European listings, with a value of $344.13 billion. In 26th place, the luxury firm led by Bernard Arnault is not going through its best moment: in its latest results for September, the company suffered the first drop in sales since the pandemic; while revenues reached $65.64 billion in the first nine months of the year, a figure that represents a 2% decline compared to the figure presented for the same period of the previous year and the worst figure in sales since the second quarter of 2020.
Third place among large European listed companies belongs to ASML. In 32nd place, the Dutch technology company reached $415.95 billion on October 10, when it overtook LVMH and became Europe’s largest listed company. However, a sharp drop in its shares a week ago relegated it, as of today, to a value of $283.56 billion. However, we expect the company to return to its strengths, with very attractive potential. which will be recovered as it emerges from the crisis it currently finds itself in. Behind her is SAPanother technological one, but of German origin. It presented its third quarter results on Tuesday, which demonstrate the good period the company is going through and its solid short-term prospects. It announced at the start of the year a restructuring which is bearing fruit, placing emphasis on AI. It currently has a capitalization of $283.56 billion.
The first pharmacist in the list corresponds to Rockoccupying the fifth place among large European listed companies. The Swiss company has a market value of $259.72 billion. The group’s sales increased by 6% over the first nine months, driven by strong demand for its drugs such as Vabysmo (serious eye diseases), Phesgo (breast cancer) and Ocrevus (multiple sclerosis). In the third quarter, the company’s sales increased by 9%, the same as in the second quarter. After her, another Swiss, but from the food sector like her Nestlewith a market value of $253.38 billion. The year 2024 will not go down in history for the company, which recorded a turnover of 77.23 billion dollars in the first nine months of 2024, or 2.4% less compared to the same period of the previous year. According to the multinational, this decline is partly attributed to exchange rate effects and weak consumer demand.
In seventh place is Hermeswith a market capitalization of $239.85 billion. It is the only luxury brand that has managed to overcome the turbulence experienced by the sector. The gala closes the first nine months of the year by increasing its sales. While LVMH and Kering ended the period with declining sales, the French luxury group ended the period with an increase in its turnover supported by the good results recorded in Asia. Concretely, Hermès ended the period with a turnover of 12.11 billion dollars, up 11.4% compared to the same period of the previous year. And all this thanks to the good behavior of the Asian consumer. In the Japan and Asia-Pacific markets, the group recorded revenue of $6.65 billion, up 6% compared to 2023. “Amid an economic and geopolitical context even more uncertain, I would like to thank all the collaborators. for the good results of the third quarter, and to our customers for their loyalty”, said Axel Dumas, executive president of Hermès, publicly.
AstraZeneca It ranks eighth, with a market value of $237.46 billion. The British company increased its revenue by 18% in the first half and raised its annual forecast. On August 31, it reached its maximum values, reaching a value of around 275 billion. Since then, the pharmaceutical company has maintained acceptable figures. Novartisalso active in the pharmaceutical sector, is the ninth listed company with the highest stock market value. The Swiss company reaches 230.86 billion dollars. And in tenth place is Accenture. The Irish company, one of the world’s largest management consultancies, closed its annual financial year with revenue of $64.9 billion, an increase of 2% on the year previous. As he explains, the multinational is growing in three of the five areas of activity: Resources (+4%); Health and public sector (+10%); Industry, Consumption and Distribution (+2%). Conversely, its activities contracted in Financial Services (-3%), Communications, Media and Technology (-4%). Its market value stands at $228.73 billion.
The most valuable European listed companies
18. Novo Nordisk: $513.37 billion – Denmark – Pharmaceutical products
26. LVMH: $344.13 billion – France – Fashion – luxury
32. ASML: $283.56 billion – Dutch – Technology
33. SAP: $275.37 billion – Germany – Technology
39. Roche: $259.72 billion – Switzerland – Health
41. Nestlé: $253.38 billion – Switzerland – Food
44. Hermès: $239.85 billion – France – Luxury fashion
45. AstraZeneca: $237.46 billion – England – Pharmaceutical products
49. Novartis: $230.86 billion – Switzerland – Pharmaceutical products
50. Accenture: $228.73 billion – Irish – Management consulting
